Alprenolol in Hypertension: An Open Assessment in General Practice

1975 ◽  
Vol 3 (5) ◽  
pp. 338-344 ◽  
Author(s):  
F L Madill ◽  
G Nyberg
Keyword(s):  
Blood Pressure ◽  
General Practice ◽  
Side Effects ◽  
Side Effect ◽  
Open Study ◽  
Diastolic Pressure ◽  
Beta Blockers ◽  
Previous Treatment ◽  
Average Dose ◽  
Average Systolic Blood Pressure

In an open study of alprenolol for hypertension in 100 patients and involving 29 practitioners, the drug was found to he capable of controlling blood pressure to a level of 120 mm Hg mean blood pressure in 79 patients, either alone or in combination with other drugs, at an average dose of 359 mg daily. The average systolic blood pressure fell from 186 to 157 mm Hg, and the average diastolic pressure fell from 112 to 95 mm Hg over 8-12 weeks. Three patients had to withdraw from treatment due to side-effects. Thirteen patients had side-effects of tolerable nature, and 16 patients with side-effects of similar severity on previous treatment suffered less or not at all when switched to alprenolol. These results are very similar to other studies of the same type using other beta-blockers, but the side-effect frequency seems to be lower with alprenolol. This is corroborated by comparative official side-effect reporting over seven years for different beta-blockers.

An Open Study of Two Dose Levels of ‘Vivalan’ (Viloxazine Hydrochloride ICI 58 834) in Depression in General Practice

1974 ◽  
Vol 2 (4) ◽  
pp. 253-259 ◽  
Author(s):  
P F C Bayliss ◽  
J W Harcup ◽  
M Mayer ◽  
R Million ◽  
J E Murphy ◽  
...  
Keyword(s):  
General Practice ◽  
Depressive Symptoms ◽  
Side Effects ◽  
Side Effect ◽  
Open Study ◽  
Anxiety Symptoms ◽  
High Dose ◽  
Dose Levels

Forty-eight mild to moderate depressives were treated by six genera practitioners with a chemically novel anti-depressant, ‘Vivalan’ (viloxazine hydrochloride, ICI 58 834). Twenty-five patients took 150 mg/day in three divided doses, and twenty-three took 200 mg/day in two divided doses, each for twenty-one days. The severity of both the depressive symptoms and the anxiety symptoms showed a statistically highly significant reduction over the duration of the study. There was no difference between the efficacy of the two dose levels. Viloxazine was generally well tolerated and there was no difference between the two dose levels as far as side-effects or withdrawals were concerned. The usual sedative and anti-cholinergic side-effects of the tricyclic anti-depressants were virtually absent. The only side-effect seen was a transient upper gastro-intestinal disturbance. It was commoner at the high dose but not significantly so. It is concluded that viloxazine hydrochloride appears to be an effective anti-depressant in this type of patient and produces little or no sedative or anti-cholinergic side-effects. Either 150 mg/day or 200 mg/day would seem a reasonable dose to use in general practice.

Treatment of Moderately Severe Essential Hypertension in General Practice with a Combination of Cyclopenthiazide with Potassium Chloride (Navidrex K) and Oxprenolol (Trasicor 80mg): A Report on 554 Patients

1974 ◽  
Vol 2 (1) ◽  
pp. 7-11 ◽  
Author(s):  
W A Forrest
Keyword(s):  
Blood Pressure ◽  
General Practice ◽  
Essential Hypertension ◽  
Side Effects ◽  
Potassium Chloride ◽  
Maximum Dose ◽  
Diastolic Pressure ◽  
Good Control ◽  
Daily Dose

Five hundred and fifty-four patients, with an initial mean diastolic pressure of 130 mm Hg, were treated with a combination of Navidrex K ( 0·5 mg daily) and up to 480 mg (six tablets daily) of Oxprenolol (Trasicor 80 mg). In 69% of this group, good control of the blood pressure was achieved with a daily dose of four tablets ( 320 mg) of Oxprenolol. In the remainder of patients significant reductions in blood pressure levels were noted, again with a mean dose of less than 320 mg daily of oxprenolol. There were indications in this group that better control of blood pressure levels might have been reached, had more of the patients been prescribed the maximum dose of 480 mg daily (six tablets) permitted in the study. Tolerability of this regime was very good. More than 80% of patients reported no side-effects at all, and one patient in four reported ‘feeling better’ after treatment.

A Multicentre Study Examining the Substitution of Trasidrex for the Free Combination of Slow-Trasicor and Navidrex-K

1979 ◽  
Vol 7 (6) ◽  
pp. 524-527 ◽  
Author(s):  
A F Ebbutt ◽  
R W Elsdon Dew
Keyword(s):  
Blood Pressure ◽  
Heart Rate ◽  
General Practice ◽  
Essential Hypertension ◽  
Side Effects ◽  
Open Study ◽  
Global Assessment ◽  
Pressure Control ◽  
Time Intervals ◽  
The Mean

A multicentre, open study of general practice patients with essential hypertension who were currently being treated with oxprenolol and cyclopenthiazide was undertaken in which the patients were transferred to Trasidrex for 12 weeks. Weight, blood pressure, heart rate and side-effects were assessed pre-trial and at 4-week intervals. A global assessment was also made at the same time intervals. The mean serum potassium remained virtually unchanged after 12 weeks treatment with Trasidrex. Blood pressure control was marginally improved during the study and it is thought possible that better patient compliance might explain this. Trasidrex was tolerated equally as well as the free combination.

scholarly journals Old hypertensive patient: a hard challenge

2013 ◽  
pp. 109-112
Author(s):  
Giuseppe Rossetti ◽  
Diana Solari ◽  
Maria Laura Rainoldi ◽  
Stefano Carugo
Keyword(s):  
Blood Pressure ◽  
Cardiovascular Risk ◽  
Elderly People ◽  
Diastolic Pressure ◽  
Beta Blockers ◽  
The Elderly ◽  
Pressure Control ◽  
World Population ◽  
Continuous Increase ◽  
Hypertensive Therapy

BACKGROUND High blood pressure is one of the most important cardiovascular risk factor and its incidence is continuously increasing: on 2025 1/3 of adult world population will suffer of it. Moreover, the therapy of elderly hypertension sufferer patient is still growing up in importance for the continuous increase of world population average life. With ageing, the cardiovascular system suffers neurohormonal and haemodinamic modifications which determine the onset of isolate systolic hypertension, which is characteristic of the elderly. This pathology results linked to a higher cardiovascular risk. AIM OF THE STUDY This review aims to analyze and evaluate present and future therapeutic opportunities about anti-hypertensive therapy in elderly people. DISCUSSION AND CONCLUSIONS Also in elderly people systolic blood pressure values must be lower than 150 mmHg, but it’s also important to maintain diastolic pressure not under 70 mmHg, to avoid phenomenons of cerebral and coronary hypo-perfusion (J curve). The benefits of an effective anti-hypertensive therapy are achieved thanks to both blood pressure lowering “per se” and to the decrease of cardiovascular mortality and morbility. Blood pressure control in the elderly is a hard challenge for the low compliance to the therapy, for the importance of the comorbidity and for the supplementary risk factors. ESH-ESC 2007 guidelines recommend for elderly highblood pressure sufferer patient the use first of all of calcium-antagonists and thiazides diuretics, and for second line ACE-inhibitors, ARB and beta-blockers. In several patients combinations of two or more drugs are necessary to obtain pressure control.

scholarly journals Suvorexant: A boon for Sleepless Nights

2016 ◽  
Vol 14 (1) ◽  
pp. 43-45
Author(s):  
Anjan Khadka ◽  
Dick Brashier ◽  
Amol Vijay Khanpure ◽  
Pem Chuki
Keyword(s):  
General Practice ◽  
Side Effects ◽  
Side Effect ◽  
Sleep Onset ◽  
Side Effect Profile ◽  
New Class ◽  
Sleep Maintenance ◽  
Nonrestorative Sleep ◽  
Arousal System ◽  
Falling Asleep

Insomnia is characterized by difficulty in falling asleep, difficulty maintaining sleep, or experiencing nonrestorative sleep. Insomnia is the most common medical complaint in general practice.  Low efficacy and various side effects limit the use of existing treatment option. Suvorexant is an orexin receptor antagonist (ORA), first in a new class of drugs in development for the treatment of insomnia. It inhibits the wakefulness-promoting orexin neurons of the arousal system thereby promoting the natural transition from wakefulness. It also improves sleep onset and sleep maintenance and has a favorable tolerability and limited side-effect profile.

General Practice Blood Pressure Recording in Scotland: Variations in the Classification of Hypertension

1996 ◽  
Vol 41 (4) ◽  
pp. 108-109
Author(s):  
B.S. Henderson ◽  
M.W. Taylor ◽  
R.M. Milne ◽  
R.J. Taylor ◽  
L.D. Ritchie ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Health Promotion ◽  
General Practice ◽  
Diastolic Pressure ◽  
Computer Software ◽  
Significant Risk ◽  
Practice Population ◽  
Wide Range ◽  
Health Promotion Activity

A questionnaire concerning blood pressure assessment, as part of health promotion activity, was circulated to all 770 Gpass practices in Scotland producing a 64.6% response rate. The results reveal a wide range in both the systolic and diastolic levels chosen to classify blood pressure as normal, borderline raised or raised. Practices are using a variety of values to indicate hypertension when considering systolic and, to a lesser extent, diastolic pressure. The variations found suggest that both over and under treatment are a significant risk to patients. The introduction of the 1993 health promotion regulations means that practices are required to actively target their practice population for blood pressure assessment and appropriate intervention. We suggest that this process will be enhanced if doctors are encouraged to adopt the established guidelines for the classification of blood pressure or general practice computer software is adapted to offer blood pressure protocol support.

Oxprenolol in Hypertension: A Report on 187 Patients in General Practice Originally Treated with Clonidine

1975 ◽  
Vol 3 (6) ◽  
pp. 395-398 ◽  
Author(s):  
W A Forrest
Keyword(s):  
Blood Pressure ◽  
General Practice ◽  
Side Effects ◽  
Receptor Antagonist ◽  
Systolic Pressure ◽  
Hypertensive Patients ◽  
Β Receptor

Substitution, in part or totally, of the β- receptor antagonist, oxprenolol, for clonidine in 187 hypertensive patients resulted in significant reduction in blood pressure levels, particularly of systolic pressure. The incidence of unwanted side-effects was markedly reduced, with an accompanying improvement in the quality of the patient's life.

Piroxicam in the Treatment of Acute Gout: A Multicentre Open Study in General Practice

1979 ◽  
Vol 7 (6) ◽  
pp. 507-510 ◽  
Author(s):  
J Eric Murphy
Keyword(s):  
General Practice ◽  
Uric Acid ◽  
General Practitioner ◽  
Side Effects ◽  
Pain Relief ◽  
Serum Uric Acid ◽  
Open Study ◽  
Acute Gout ◽  
Highly Effective

Twenty-nine patients with acute gout were treated with piroxicam (40 mg daily for 5 days) in a multicentre general practitioner study. Pain relief was noticeable within 4 hours of the first dose and thereafter proceeded steadily, together with the early relief of other sypmtoms associated with acute gout. The prompt relief of symptoms was accompanied by a fall in serum uric acid. Piroxicam was well tolerated, eight patients experiencing side-effects that were mainly mild and gastro-intestinal in nature. The drug seems to be highly effective and safe in the treatment of acute gout.

An Assessment of the Anti-Anginal Effect of Tolamolol, a New Beta-Blocking Agent

1975 ◽  
Vol 3 (6) ◽  
pp. 399-406 ◽  
Author(s):  
A Williams ◽  
M C Holt
Keyword(s):  
Blood Pressure ◽  
Heart Rate ◽  
Side Effects ◽  
Open Study ◽  
Laboratory Tests ◽  
Statistical Significance ◽  
Blocking Agent ◽  
Anginal Attack ◽  
Routine Laboratory ◽  
Beta Blocking

The anti-anginal activity of a new beta-blocking agent, tolamolol, was investigated in an open study. Seventeen patients ( fourteen males, three females) from two centres were given tolamolol in doses varying from 150 mg to 800 mg daily for periods of between one and thirty-four weeks. Records were made of the number of attacks of angina and of the consumption of sublingual glyceryl trinitrate ( GTN). Blood pressure and heart rate were monitored together with possible side-effects and the results of routine laboratory tests. There was an over-all reduction in anginal attack rates and the number of GTN tablets used, although these did not reach statistical significance in the small numbers concerned. Heart rate and blood pressure were similarly reduced. Side-effects were of mild severity and were tolerated or disappeared with continued treatment.

Sign in / Sign up

Export Citation Format

Share Document